Based on the Bausch Health Companies Inc stock forecast from 2 analysts, the average analyst target price for Bausch Health Companies Inc is USD 9.00 over the next 12 months. Bausch Health Companies Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Bausch Health Companies Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Bausch Health Companies Inc’s stock price was USD 7.31. Bausch Health Companies Inc’s stock price has changed by +18.67% over the past week, -5.31% over the past month and -21.40% over the last year.
No recent analyst target price found for Bausch Health Companies Inc
No recent average analyst rating found for Bausch Health Companies Inc
Company Overview Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. Read Less
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, inter...Read More
Frequently Asked Questions About Bausch Health Companies Inc (BHC) Stock
Based on ratings from 2 analysts Bausch Health Companies Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on BHC's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for BHC is USD 9.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 8.
BHC stock's Price/Earning ratio is 71.75.
Our analysis grades BHC stock's Price / Earning ratio at F. This means that BHC stock's Price/Earning ratio is above 75% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this BHC may be a overvalued for its sector.
The last closing price of BHC's stock was USD 7.31.
The most recent market capitalization for BHC is USD 2.41B.
Based on targets from 2 analysts, the average taret price for BHC is projected at USD 9.00 over the next 12 months.
This means that BHC's stock price may go up by +23.12% over the next 12 months.
We can't find any ETFs which contains Bausch Health Companies Inc's stock.
As per our most recent records Bausch Health Companies Inc has 20,270 Employees.
Bausch Health Companies Inc's registered address is 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8.
You can get more information about it from Bausch Health Companies Inc's website at https://www.bauschhealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bausch Health Companies Inc (BHC) Stock
Based on ratings from 2 analysts Bausch Health Companies Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on BHC's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for BHC is USD 9.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 8.
BHC stock's Price/Earning ratio is 71.75.
Our analysis grades BHC stock's Price / Earning ratio at F. This means that BHC stock's Price/Earning ratio is above 75% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this BHC may be a overvalued for its sector.
The last closing price of BHC's stock was USD 7.31.
The most recent market capitalization for BHC is USD 2.41B.
Based on targets from 2 analysts, the average taret price for BHC is projected at USD 9.00 over the next 12 months.
This means that BHC's stock price may go up by +23.12% over the next 12 months.
We can't find any ETFs which contains Bausch Health Companies Inc's stock.
As per our most recent records Bausch Health Companies Inc has 20,270 Employees.
Bausch Health Companies Inc's registered address is 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8.
You can get more information about it from Bausch Health Companies Inc's website at https://www.bauschhealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BHC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
